FirmaIQ
Org.nr 923 831 762 2022 → 2023 Year-over-year analysis

ADJUTEC PHARMA AS: årsregnskap 2023 vs 2022

Shrank 6% on revenue, stronger earnings, cash halved-plus

approved 2024-05-28; registry 2024-06-14; journal 2024 470099

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2023 with 2022 for ADJUTEC PHARMA AS. Revenue 7.84m NOK → 7.33m NOK (-6.5%). Net result -17.15m NOK → -9.53m NOK. Equity 27.60m NOK → 18.07m NOK.

On the constructive side: operating result improved; net result improved. Pressures included: revenue fell; equity eroded; cash fell.

Also worth watching: sharp cash drawdown. All figures are taken from the published annual accounts for ADJUTEC PHARMA AS.

At a glance

Scorecard

Revenue
7.84m NOK 7.33m NOK
-6.5%
Operating result
-23.40m NOK -13.05m NOK
+44.2%
Net result
-17.15m NOK -9.53m NOK
+44.4%
Equity
27.60m NOK 18.07m NOK
-34.5%
Cash
25.64m NOK 6.34m NOK
-75.3%
Total assets
33.99m NOK 18.09m NOK
-46.8%

What improved

  • ↑

    Operating result improved

    Operating result -23.40m NOK → -13.05m NOK (op. margin -298.3% → -177.9%). Calculated

  • ↑

    Net result improved

    Net result -17.15m NOK → -9.53m NOK (net margin -218.7% → -130.0%). Calculated

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 7.84m NOK to 7.33m NOK (-6.5% YoY). Calculated

  • ↓

    Equity eroded

    Book equity 27.60m NOK → 18.07m NOK (equity ratio 81.2% → 99.9%). Calculated

  • ↓

    Cash fell

    Bank deposits 25.64m NOK → 6.34m NOK (-75.3% YoY). Calculated

Things to notice

  • ·

    Sharp cash drawdown

    Cash fell by more than 60% YoY (25.64m NOK → 6.34m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation